Literature DB >> 16239295

Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes.

U Kini1, N Adab, J Vinten, A Fryer, J Clayton-Smith.   

Abstract

BACKGROUND: In utero exposure to antiepileptic drugs (AEDs) can result in several different teratogenic effects including major malformations, dysmorphic facial features, and learning and behavioural problems. It is estimated that there is a 2-3-fold increase in the risk of malformations compared with the general population. The risk of cognitive impairment and behavioural problems is less clear.
OBJECTIVE: To report the frequency and specificity of individual dysmorphic features and to relate the dysmorphic facial phenotype to developmental outcome.
METHODS: A retrospective study of 375 children born to 219 mothers with epilepsy. The age of the study group ranged from 6 months to 16 years. Each child underwent a physical examination and a battery of neuropsychological tests. Dysmorphic features were scored from photographs on a blind basis by a panel of dysmorphologists.
RESULTS: A total of 274 children were exposed to AEDs (63 to valproate, 94 to carbamazepine, 26 to phenytoin, 15 to other monotherapies, and 76 to polytherapy). Major malformations were identified in 14% of children exposed to valproate in utero, 5% exposed to carbamazepine, and 4% in the non-exposed group. Overall, 47% of exposed children were correctly identified as having been exposed to AEDs in utero. There was a significant correlation between verbal intelligence quotient and dysmorphic facial features in the valproate exposed children only.
CONCLUSION: Children exposed to valproate have more distinctive facial features, but a subtle and distinctive facial phenotype is also seen in children exposed to carbamazepine. Nearly half (45%) of unexposed children had some of the facial features associated with AED exposure, showing that many of these features may be seen as part of normal variation and that the diagnosis of the fetal anticonvulsant syndrome is difficult to make on the basis of facial gestalt alone. Developmental surveillance should be offered to children with prenatal exposure to AEDs, particularly those with exposure to high doses of valproate.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239295      PMCID: PMC2672688          DOI: 10.1136/adc.2004.067421

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  22 in total

1.  The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age.

Authors:  D Vanoverloop; R R Schnell; E A Harvey; L B Holmes
Journal:  Neurotoxicol Teratol       Date:  1992 Sep-Oct       Impact factor: 3.763

2.  The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort.

Authors:  J G Omtzigt; F J Los; D E Grobbee; L Pijpers; M G Jahoda; H Brandenburg; P A Stewart; H L Gaillard; E S Sachs; J W Wladimiroff
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

3.  A case definition and photographic screening tool for the facial phenotype of fetal alcohol syndrome.

Authors:  S J Astley; S K Clarren
Journal:  J Pediatr       Date:  1996-07       Impact factor: 4.406

4.  Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy.

Authors:  A Ornoy; E Cohen
Journal:  Arch Dis Child       Date:  1996-12       Impact factor: 3.791

5.  Fetal valproate syndrome.

Authors:  J Clayton-Smith; D Donnai
Journal:  J Med Genet       Date:  1995-09       Impact factor: 6.318

6.  Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy.

Authors:  D Scolnik; I Nulman; J Rovet; D Gladstone; D Czuchta; H A Gardner; R Gladstone; P Ashby; R Weksberg; T Einarson
Journal:  JAMA       Date:  1994-03-09       Impact factor: 56.272

7.  Pattern of malformations in the children of women treated with carbamazepine during pregnancy.

Authors:  K L Jones; R V Lacro; K A Johnson; J Adams
Journal:  N Engl J Med       Date:  1989-06-22       Impact factor: 91.245

8.  Psychomotor development in children of mothers with epilepsy.

Authors:  M L Granström; E Gaily
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

Review 9.  Toluene embryopathy: delineation of the phenotype and comparison with fetal alcohol syndrome.

Authors:  M A Pearson; H E Hoyme; L H Seaver; M E Rimsza
Journal:  Pediatrics       Date:  1994-02       Impact factor: 7.124

Review 10.  Verification of the fetal valproate syndrome phenotype.

Authors:  H H Ardinger; J F Atkin; R D Blackston; L J Elsas; S K Clarren; S Livingstone; D B Flannery; J M Pellock; M J Harrod; E J Lammer
Journal:  Am J Med Genet       Date:  1988-01
View more
  20 in total

1.  Exposure to Sodium Valproate during Pregnancy: Facial Features and Signs of Autism.

Authors:  Rachel Stadelmaier; Hanah Nasri; Curtis K Deutsch; Margaret Bauman; Anne Hunt; Christopher J Stodgell; Jane Adams; Lewis B Holmes
Journal:  Birth Defects Res       Date:  2017-06-21       Impact factor: 2.344

2.  Treatment options in juvenile myoclonic epilepsy.

Authors:  Laura Mantoan; Matthew Walker
Journal:  Curr Treat Options Neurol       Date:  2011-08       Impact factor: 3.598

3.  Fetal valproate syndrome: the Irish experience.

Authors:  Hamizah Mohd Yunos; Andrew Green
Journal:  Ir J Med Sci       Date:  2018-02-03       Impact factor: 1.568

4.  Severe consequences of carbamazepine exposure in utero.

Authors:  Antonio Bravo; Dolores Hernandez; Laura Martinez-Villarreal; Gabriela Elizondo; Carmen Esmer
Journal:  BMJ Case Rep       Date:  2011-08-04

Review 5.  Cognitive/behavioral teratogenetic effects of antiepileptic drugs.

Authors:  Kimford J Meador; Gus Baker; Morris J Cohen; Eija Gaily; Michael Westerveld
Journal:  Epilepsy Behav       Date:  2007-11       Impact factor: 2.937

Review 6.  Do lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy?

Authors:  John J Craig
Journal:  Obstet Med       Date:  2012-02-20

Review 7.  Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study.

Authors:  Janneke Jentink; Helen Dolk; Maria A Loane; Joan K Morris; Diana Wellesley; Ester Garne; Lolkje de Jong-van den Berg
Journal:  BMJ       Date:  2010-12-02

Review 8.  Managing epilepsy in women of childbearing age.

Authors:  Pamela M Crawford
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 9.  Cognitive abilities and behaviour of children exposed to antiepileptic drugs in utero.

Authors:  Rebecca L Bromley; Gus A Baker; Kimford J Meador
Journal:  Curr Opin Neurol       Date:  2009-04       Impact factor: 5.710

Review 10.  Long-term consequences after exposure to antiepileptic drugs in utero.

Authors:  Lisa Forsberg; Katarina Wide
Journal:  Ther Adv Drug Saf       Date:  2011-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.